1. A Meta-Analysis on the Relations between EGFR R521K Polymorphism and Risk of Cancer
   Yinsheng Wang et al, 2014, International Journal of Genomics CrossRef
2. The Association between Epidermal Growth Factor Receptor (EGFR) Gene Polymorphisms and Lung Cancer Risk
   Nabil Bashir et al, 2018, Biomolecules CrossRef
3. Associations Between Genetic Polymorphisms of Epidermal Growth Factor Receptor (EGFR) and Survival of Colorectal Cancer (CRC) Patients Treated with 5-Fluorouracil-Based Chemotherapy
   Ching-Yu Lai et al, 2013, Ann Surg Oncol CrossRef
4. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
   Giuseppe Bronte et al, 2014, Critical Reviews in Oncology/Hematology CrossRef
5. Targeted Knock-in of the Polymorphism rs61764370 Does Not AffectKRASExpression but Reduces let-7 Levels
   Emily Hannah Crowley et al, 2014, Human Mutation CrossRef
6. Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer
   Hongying Lv et al, 2014, Med Oncol CrossRef
7. Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
   Xiaoqing Zhang et al, 2016, Tumor Biol. CrossRef
8. Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib
   Anne Winther-Larsen et al, 2015, Lung Cancer CrossRef
9. Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study
   Matam Kavitha et al, 2015, Asian Pacific Journal of Cancer Prevention CrossRef
10. On the pharmacogenetics of non-small cell lung cancer treatment
    Mariacarmela Santarpia et al, 2016, Expert Opinion on Drug Metabolism & Toxicology CrossRef
11. EGFR Polymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis.
    Vladimir Jurisic et al, 2020, J Oncol CrossRef
12. Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer
    Niels Heersche et al, 2022, Drug Resistance Updates CrossRef
13. Investigating the importance of EGFR (− 216G/T), Exo1 (K589E) and LEP (− 2548G/A) gene polymorphisms with risk of lung cancer as potential diagnostic biomarker in Iranian population
    Milad Pezeshki et al, 2023, Egypt J Med Hum Genet CrossRef